Lunsekimig

生产企业：Sanofi

Sanofi's investigational bispecific nanobody that blocks both TSLP and IL-13; in Phase 2b/3 development for asthma and COPD.

医学正文保留数据源原文，避免将未经专业审核的机器翻译呈现为临床事实。

概览

Sanofi's investigational bispecific nanobody that blocks both TSLP and IL-13; in Phase 2b/3 development for asthma and COPD.

Bispecific nanobody that simultaneously blocks TSLP and IL-13.

每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。